ahlam1399
09-23-2016, 02:30 PM
BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drug
* GSK an**unces regulatory submissions for subcutaneousformulation of Benlysta (Belimumab) for patients with systemiclupus diseasehttp://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=hlZMvatIxV0:DeHGptmkxRk:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=hlZMvatIxV0:DeHGptmkxRk:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/hlZMvatIxV0
* GSK an**unces regulatory submissions for subcutaneousformulation of Benlysta (Belimumab) for patients with systemiclupus diseasehttp://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=hlZMvatIxV0:DeHGptmkxRk:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=hlZMvatIxV0:DeHGptmkxRk:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=hlZMvatIxV0:DeHGptmkxRk:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/hlZMvatIxV0